Pharmacological treatment of COPD: the devil is always in the detail

Keywords

• Humans
• Practice Guidelines as Topic
• Precision Medicine/*standards
• Pulmonary Disease, Chronic Obstructive/diagnosis/*drug therapy
• Peptinnovate and Skyepharma, as well as grants and personal fees from
• AstraZeneca, Boehringer Ingleheim, Chiesi, Cipla, GlaxoSmithKline, Glenmark,
• Menarini, Merck, Mundipharma, Novartis, Pfizer, Pulmatrix, Teva, Therevance and
• Verona, outside the submitted work. Conflict of interest: P. Barnes reports
• grants and personal fees from AstraZeneca and Boehringer Ingelheim, personal fees
• from Novartis, Chiesi, Menarini and Teva, and grants from Heptaris, during the
• conduct of the study. Conflict of interest: C. Vogelmeier reports personal fees
• from Almirall, Cipla, Berlin Chemie/Menarini, CSL Behring and Teva, and grants
• and personal fees from AstraZeneca, and Boehringer Ingelheim, Chiesi,
• GlaxoSmithKline, Grifols, Mundipharma, Novartis and Takeda. He has also received
• grants from German Federal Ministry of Education and Research (BMBF) Competence
• Network Asthma and COPD (ASCONET), Bayer Schering Pharma AG, MSD and Pfizer,
• outside the submitted work. Conflict of interest: A. Agusti reports grants and
• personal fees from AstraZeneca and Menarini, and personal fees from Chiesi, TEVA
• and Novartis, outside the submitted work.